Pyruvate Dehydrogenase Kinase 4 Promotes Vascular Calcification via SMAD1/5/8 Phosphorylation

Vascular calcification, a pathologic response to defective calcium and phosphate homeostasis, is strongly associated with cardiovascular mortality and morbidity. In this study, we have observed that pyruvate dehydrogenase kinase 4 (PDK4) is upregulated and pyruvate dehydrogenase complex phosphorylat...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 5; no. 1; p. 16577
Main Authors Lee, Sun Joo, Jeong, Ji Yun, Oh, Chang Joo, Park, Sungmi, Kim, Joon-Young, Kim, Han-Jong, Doo Kim, Nam, Choi, Young-Keun, Do, Ji-Yeon, Go, Younghoon, Ha, Chae-Myeong, Choi, Je-Yong, Huh, Seung, Ho Jeoung, Nam, Lee, Ki-Up, Choi, Hueng-Sik, Wang, Yu, Park, Keun-Gyu, Harris, Robert A., Lee, In-Kyu
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 12.11.2015
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Vascular calcification, a pathologic response to defective calcium and phosphate homeostasis, is strongly associated with cardiovascular mortality and morbidity. In this study, we have observed that pyruvate dehydrogenase kinase 4 (PDK4) is upregulated and pyruvate dehydrogenase complex phosphorylation is increased in calcifying vascular smooth muscle cells (VSMCs) and in calcified vessels of patients with atherosclerosis, suggesting that PDK4 plays an important role in vascular calcification. Both genetic and pharmacological inhibition of PDK4 ameliorated the calcification in phosphate-treated VSMCs and aortic rings and in vitamin D 3 -treated mice. PDK4 augmented the osteogenic differentiation of VSMCs by phosphorylating SMAD1/5/8 via direct interaction, which enhances BMP2 signaling. Furthermore, increased expression of PDK4 in phosphate-treated VSMCs induced mitochondrial dysfunction followed by apoptosis. Taken together, our results show that upregulation of PDK4 promotes vascular calcification by increasing osteogenic markers with no adverse effect on bone formation, demonstrating that PDK4 is a therapeutic target for vascular calcification.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ISSN:2045-2322
2045-2322
DOI:10.1038/srep16577